Drug Approval | August 22, 2022
USFDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks
Covaxin was earlier approved for children 12-18 years of age
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Subscribe To Our Newsletter & Stay Updated
